GBA1 and Parkinson disease: The GCase replacement by Cerezyme significantly reduced monomeric α-synuclein protein levels by 26% (Fig. 4 D and E) and increased both the pro and mature CTSD protein levels (Fig. 4 F—I) in GBA1 mutation (N370S/WT) PD neurons.